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Abstract Heart failure is a major economic and
public health problem. Despite the recent advances in
drug therapy and coronary revascularization, the lost
cardiomyocytes due to necrosis and apoptosis are not
replaced by new myocardial tissue. Cell therapy is an
interesting therapeutic option as it potentially
improves contractility and restores regional ventric-
ular function. Early clinical data demonstrated that
cell transplantation, mainly delivered through non-
surgical methods, is safe and feasible. However,
several important issues need to be elucidated. This
includes, next to determining the best cell type, the
optimal delivery strategy, the biodistribution and the
survival of implanted stem cells after transplantation.
In this view, pre-clinical animal experiments are
indispensable. Reporter genes, magnetic or radioac-
tive labeling of stem cells have been developed to
observe the fate and the distribution of transplanted
cells using non-invasive imaging techniques. Several
studies have demonstrated that these direct and non-
direct labeling techniques may become an important
tool in cell therapy. Integration of cell delivery and
cell tracking will probably be a key for the success of
cell therapy in patients. This review will provide a
comprehensive overview on the various cell tracking
and non-surgical cell delivery techniques, which are
highly important in view of experimental and clinical
studies.
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Coronaryheartdisease isa major public andeconomic
health problem leading to more than 7 million deaths
world wide each year [1, 2]. Optimal pharmacologic
treatmentandcoronaryreperfusiontherapyhaveledto
improved survival of patients with coronary artery
disease. Clearly, current therapies can not replace
dysfunctional or lossed cardiomyocytes which ﬁnally
lead to heart failure. A structural solution may be
provided by cell therapy which has emerged as a
potential new therapeutic strategy. Cell therapy is
consideredinthesettingofacutemyocardialinfarction
(MI) and chronic ischemic heart failure. The ultimate
goals of cell therapy are myocardial regeneration and
revascularization,therebyre-establishingsynchronous
contractility and bioelectrical conductivity to achieve
overall clinical improvement of cardiac function
without severe adverse effects. Transplantation strat-
egies include percutaneous, surgical and systemic
delivery of various types of stem cells [3–7]. To
monitor the efﬁciency of implanted stem cells, most
small animal studies use post mortem histology as a
gold standard [8, 9]. For in vivo detection of cell
retention, sophisticated imaging techniques are neces-
sary. Additionally, non-invasive imaging is preferred
to determine the effect of cell therapy on cardiac
function(e.g.volume,massandpressure).Nowadaysit
ispossibletotrackandquantifytransplantedstemcells
by direct and non-direct labeling techniques using (1)
nuclearimaging[positronemissiontomography(PET)
or single photon emission computer tomography
(SPECT)] and (2) magnetic resonance imaging
(MRI). Various clinically approved radiomarkers are
suggested to be useful in cardiac cellular therapies like
18F-ﬂuorodeoxyglucose (
18F-FDG) for PET scan,
indium
111 (In
111) for SPECT and superparamagnetic
iron oxide (SPIO) for MRI [10–12].
It is important to further optimize delivery strat-
egies in view of ongoing (pre-) clinical studies for
regenerative therapy. To this end, state-of-the-art cell
tracking is highly necessary. This review will provide
a robust update of available in vivo cell tracking
strategies and non-surgical delivery techniques that
will guide experimental set up of pre-clinical stem
cell research.
Part 1: in vivo cell tracking strategies
In the following section the contrast agents and
detectors that have been proposed for non-invasive
cell tracking will be discussed. Thereafter, we will
review the advantages and disadvantages of each
imaging strategy and suggest future directions for
research. Figure 1 and Table 1 will provide an
overview of all available direct and non-direct
labeling techniques.
Fig. 1 Different methods
for non-invasive cell
tracking. a MRI magnetic
resonance imaging, SPIO
super paramagnetic iron
oxide; b SPECT single
photon emission computer
tomography, indium
111
In
111, 99Tc 99Technetium,
PET positron emission
tomography,
18F FDG 18F-
ﬂuorodeoxyglucose; c RPG
reporter gene
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For MRI, Gadolinium- and iron-based contrast agents
can be used for direct labeling of stem cells.
Gadolinium is bio-incompatible, cytotoxic in unch-
elated form and has a low relaxivity; therefore it is an
unattractive agent for stem cell imaging. However,
novel Gadolinium-based particles are being investi-
gated for this purpose, albeit not yet in the heart [13].
In 1996, SPIO’s (30–200 nm) were approved as
iron-based contrast agents for clinical use by the US
Food and Drug Administration (Feridex, Guerbet,
France). SPIO’s are composed of an iron oxide core
that is coated with a polymer shell to prevent aggre-
gation. The polymer may contain dextran, polyethyl-
eneglycolorstarch. The ironisbiocompatibleandcan
be recycled by cells using regular biochemical path-
ways. Labeling of targeted cells is accomplished by
endocytosis.Inaddition,efﬁciencycanbeimprovedby
using peptides/antibodies [14], magnetodendrimers
[15]ortransfectionagents[16].Labeledcellsappeared
to be hypo intense in T2*- and T2-weighted images.
Numerous studies have shown that mesenchymal
stem cells (MSC) can be labeled without affecting in
vitro cell viability, proliferation and differentiation
into adipogenic and osteogenic lineages by iron
contrast agents [10, 16, 17]. Recently, pre-clinical
studieswereabletodetectaminimumofabout 10
5pig
MSC using different sized iron particles with a
conventional cardiac MRI [10, 12]. Figure 2 shows
anexampleofcelltrackingbycardiacMRIusingSPIO
labeled MSC from our own laboratory. Detection of
Table 1 Methods of direct and non-direct stem cell tracking
Method Label Advantages Disadvantages
Direct labeling
MRI Gadolinium Simple method Bio-incompatible
Cytotoxic in unchelated form
Low relaxivity
SPIO Biocompatible
Cell friendly
High resolution
Stem cell imaging and anatomical function
can be assessed simultaneously
Long incubation time for labeling
Dilution of the contrast
Signal may not reﬂect living cells
Not suitable for patients with intracardiac
deﬁbrillator or pacemaker
SPECT In
111
99Tc
High sensitivity
Stem cell imaging and perfusion can be assessed
simultaneously
Radiation exposure to patients and neighbouring
cells
Low cellular retention
Possible effect of radioactivity on transplanted cells
Signal may not reﬂect living cells
Signal loss due to radioactive decay
PET
18F-FDG High spatial resolution
No cytotoxicity
Stem cell imaging and myocardial vitality
can be assessed simultaneously
Radiation exposure to patients
Signal may not reﬂect living cells
Signal loss due to radioactive decay
Non-direct labeling
RPG Reporter genes/
probes
Detection of viable cells
Observation of cell differentiation
Cellular dysfunction or death
Immunogenicity of gene products
Potential risk of uncontrolled growth
and malignancy
Costs
Not used in patient studies
MRI magnetic resonance imaging, SPIO super paramagnetic iron oxide, SPECT single photon emission computer tomography,
In
111 indium
111,
99Tc
99technetium, PET positron emission tomography,
18F-FDG
18F-ﬂuorodeoxyglucose, RPG reporter gene
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123stem cells mainly depends on (1) magnetic ﬁeld
strength, (2) number of cells injected, (3) labeling
efﬁciency and (4) cell size.
A practical drawback of iron-based contrast agents
is that labeling is not permanent and self-replicable.
Dilution of the contrast due to cellular fragmentation,
fusion, division and migration also limits the use for
follow-up after cell delivery. Also, variation in
labeling efﬁciency among different cell types is
present. For instance, SPIO-registered MR signals are
still detectable in embryonic stem cells [18] 5 weeks
after transplantation and 4–16 weeks for skeletal
myoblasts [19] and MSC in murine models [20],
respectively. Very little is known about the long-term
survival after cell delivery in both pre-clinical models
and humans. Furthermore, iron particles may still
remain in situ and can be taken up by phagocytotic
cells (e.g. cardiac macrophages) after cellular death
[21]. Thus, MRI signal is still present leading to
overestimation of the outcome of cellular survival
(‘false positive’ results). Another potential drawback
is negative image contrast artifacts due to air or
hemorrhage after cell injection. Finally, patients with
an intracardiac deﬁbrillator or pacemaker are no
candidates for MRI.
Magnetic resonance imaging has become an
appropriate imaging modality for stem cell tracking
and therapeutic efﬁcacy, without ionic radiation, high
spatial resolution and detailed anatomical function.
Nevertheless, at present this method is only useful for
establishing initial retention of cells as it provides
little evidence for long-term viability or functionality
of transplanted cells. None of the MRI contrast agents
have been used in the clinical ﬁeld to monitor cellular
survival. More information about long-term cell
tracking and effects on cell behavior (e.g. differen-
tiation and proliferation) in large animal studies is
mandatory before applying this technique to clinical
stem cell trials.
SPECT
Several radioisotopes are available for stem cell
tracking in the heart, Technetium (
99Tc) (T 6h )
and In
111 (T 2.6 days). Labeling is based on
established clinical protocols for white blood cells
and performed by chelating agents that carry the
radionuclides into the cell. Radioactivity is measured
by a Gamma camera composing a 3D image.
In vitro studies have shown that cell integrity of
both human and canine MSC, and endothelial
progenitor cells (EPC) were unaffected after In
111
labeling with 0,14-30 Becquerel per cell [22–24].
However, radiation induced cell damage was found
after labeling hematopoietic progenitor cells (HPC)
with In
111 [25, 26]. In addition, low cellular retention
after labeling was observed in all cell types [26–28].
Penicka et al. [29] observed high retention of
99Tc
inside bone marrow mononuclear cells (BM-MNC)
and no altered proliferation pattern after labeling.
Cell viability of MSC was also not inﬂuenced by
99Tc
[30]. The effect on cell differentiation was not
determined in these studies. The use of SPECT is
accompanied by a low detection threshold of about
10
4 cells [24] and therefore it is an attractive tool to
determine in vivo biodistribution.
Both isotopes have been studied in various large
animal models to determine cellular homing after
surgical, intramyocardial (IM) and intravenous (IV)
delivery [12, 27, 31, 32]. It was shown that a low
number of cells accumulate in the heart after
injection. However, when injecting cells into healthy
myocardium 1/3 of the total radioactivity was still
located in the heart [33]. Figure 3 shows a typical
example of cellular retention of radioactive labeled
stem cells after surgical injection in one of our
experiments. Zhou et al. [34] showed that it is
possible to simultaneously assess stem cell imaging
Fig. 2 T2* image of SPIO labeled MSC (arrow) after
transepicardial injection in healthy myocardium
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123and perfusion in a rat model using dual isotope
SPECT by combining both In
111 (for cell imaging)
and
99Tc (for perfusion study). This interesting
ﬁnding should be conﬁrmed in a pre-clinical model.
In humans, SPECT was employed to study the
kinetics of
99Tc or In
111 labeled progenitor cells after
intracoronary (IC) delivery in a small number of
patients with ischemic heart disease. In general, low
retention rates of progenitor cells (\10%) to the
infarcted myocardium were found 1–2 h after injec-
tion [29, 35, 36]. Signal loss due to reduction in
activity also limits the use of radioisotopes for long-
term follow-up.
Single photon emission computer tomography is
an attractive approach to determine delivery efﬁ-
ciency. In Table 3, all studies on cell delivery
efﬁciency are summarized per strategy. Animal
studies have shown that SPECT imaging is a
promising tool to visualize in vivo migration patterns
and to assess functional effects of transplanted stem
cells. However, the negative effect of radioisotopes
on cell behavior (e.g. radiation induced cell damage,
possible reduced differentiation rates) can not be
neglected in view of clinical use.
PET
Positron emission tomography is a well known
method to determine myocardial viability and perfu-
sion by injecting
18F-FDG. It is possible to label stem
cells with
18F-FDG to monitor homing and
biodistribution (see Table 3). No cytotoxicity, or
impaired stem cell differentiation were documented
after
18F-FDG labeling. This could be due to the
radioactive properties of
18F-FDG, that emits a long
range beta particle and thereby prevents radiation
injury inside the cell. Although PET imaging offers
high spatial resolution, the short half lifetime remains
an obstacle for long-term cell tracking.
In a porcine MI model, dynamic cell tracking of
percutaneous implemented
18F-FDG labeled circulat-
ing progenitors cells was demonstrated: only 8–18%
of myocardial activity was retained 1 h after IC
delivery [37]. Similar results were obtained when
autologous BM-MNC’s were infused to the heart
[38]. In addition,
18F-FDG was used to label and
determine myocardial homing and biodistribution of
BM-MNC after IC and IV delivery in post-acute MI
patients. Low amount of BM-MNC activity was
detected in the infarcted myocardium after injection
(less than 3%) [11]. Both studies demonstrate the
importance of metabolic myocardial imaging to
determine cellular survival and a potential effect on
scar tissue. However, larger (pre) clinical randomized
studies on this topic are required to establish early
and late biodistribution after cell delivery. Further-
more, a metabolic isotope with a longer half lifetime
is necessary for chronic cell tracking.
Reporter genes
To solve limitations in traditional cardiovascular
imaging (i.e. false positive ﬁndings after cell death
and cell toxicity), reporter genes (RPG) may be an
attractive alternative. In short, a genetically engi-
neered gene (the RPG) is incorporated into the
genome of a cell prior to transplantation. The gene
product should only be expressed by engrafted and
still viable cells. Next, cells can be visualized after IV
injection of an imaging tracer that targets the gene
product. By its presence, the survival of the graft is
certain because expression of the RPG and activity of
the gene product depends on the viability of trans-
planted cells. Enzyme, transport and receptor based
gene products are available for molecular imaging.
This strategy is particular well suited to overcome
dilution effects which ensure long-term serial imag-
ing of living transplanted stem cells. Also, repeti-
tive imaging is possible and does not depend on
decay of the radioisotope. Potential disadvantages
Fig. 3 SPECT image of indium
111 labeled MSC in the heart
after surgical injection in the left ventricle wall in a healthy
porcine model
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123include (1) costs, (2) cellular dysfunction or death,
(3) immunogenicity of gene products, (4) potential
risk of uncontrolled growth and malignancy; these
aspects preclude clinical application in patients at
this time. Several RPG’s (transferrin receptor (TR),
herpes simplex virus type 1 thymidine kinase
(HSV1) and human sodium/iodide symporter) have
been developed for non-invasive imaging in living
animals [39–41]. The transferrin receptor has been
proposed as a RPG for MRI [42]. High expression of
TR on the cell membrane leads to increased iron
uptake that is detectable by MRI and does not
depend on intracellular iron concentration. More-
over, detection may be improved by covalent
binding with iron nanoparticles [42]. However,
accumulation of iron may lead to high levels of
intracellular iron and diminished cellular function.
Furthermore, not much is known about efﬁcacy and
safety of TR in large animal models and humans.
Herpes simplex virus type 1 thymidine kinase is
being used for nuclear imaging [40]. Radioisotopes
analogous to thymidine and guanosine are used as
tracers. After metabolizing, the substrate is trapped
intracellularly. Free radioactivity is detectable by
PET or SPECT. In 2003, feasibility was tested to
monitor survival of cardiomyoblasts after IM deliv-
ery using HSV1 thymidine kinase RPG. It was
shown that optical imaging was more sensitive for
detecting cardiomyoblasts (5 9 10
5) than PET
(3 9 10
6)[ 40, 43]. Furthermore, HSV1 thymidine
kinase can be transduced in human MSC and
visualized in a clinical relevant swine model with
healthy myocardium [44]. In 2008, Gyo ¨ngyo ¨si et al.
[45] demonstrated the feasibility of PET and optical
imaging of the stable expressed of the trifusion gene
protein (luciferase) for in vivo non-invasive tracking
of IM injected MSC in a relevant animal model with
survival up to 10 days after injection. Data on HSV1
thymidine kinase and long-term follow-up are
currently not available.
Human sodium/iodide symporter controls the
membrane conductance of sodium and iodine. It is
mainly expressed in the thyroid gland, and it is absent
in cardiac cells [46]. Therefore, isotopes for both PET
and gamma camera can be used to image cells that
express this gene. More detailed information about
the effect of sodium inﬂux on cardiomyocytes is
required before entering the clinical ﬁeld.
So far, the available data is limited to reveal the
role of RPG in cellular tracking. Up till now, just one
study attempted to initiate RPG imaging in an
ischemic large animal model. Before human admin-
istration, a safe and stable RPG with no effect on cell
behavior has to be developed. In parallel, optimal
detection signal and more efﬁcient delivery routes
have to be established. Nevertheless, in our view
RPG is a promising concept for reliable cell tracking
with respect to pre-clinical studies that address
optimal cell delivery strategies and chronic long-
term follow-up.
Comparison of imaging techniques
At present, various direct and non-direct labeling
strategies have been investigated for in vivo cell
tracking. No technique has emerged as the most
optimal tracking method. Fate and biodistribution
after IV delivery by colabeling allogenic MSC with
In
111 and SPIO was observed. Migration of low
amount of cells to the heart could be detected by
SPECT, but not by MRI [12]. A combined approach
using SPECT and cardiac MRI was used to determine
function and precise visualization of In
111 labeled
stem cells in an ischemic rat model [47]. Simulta-
neous detection of stem cells and imaging of both
perfusion deﬁcit and myocardial function of the
ischemic area was done by signal coregistration.
Bioluminescence ﬁreﬂy luciferase RPG was more
accurate compared to SPIO for long-term cell
survival using optical and magnetic imaging [48].
In patients, imaging is mainly performed to
determine the effect of cell therapy on myocardial
function and perfusion. To the best of our knowledge,
no direct clinical comparison between imaging tech-
niques has been performed to observe homing and
distribution of transplanted human stem cells.
In summary, nuclear imaging is more sensitive
than MRI for short-term cell tracking. For high
spatial resolution and evaluation of cardiac function
MRI is more appropriate. In case of long-term
follow-up, iron particles and RPG can play an
important role. In our view, a multimodality
approach using both magnetic and nuclear radio-
agents in combination with RPG would provide a
solution to current limitations in cell tracking in the
near future.
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123Part 2: non-surgical methods of cell delivery
The main objective of various cell delivery methods
is to inject sufﬁcient number of cells into the
myocardium and to keep maximum retention of cells
within the area of interest. A summary of the different
cell delivery routes in clinical and pre-clinical setting
will be provided (Fig. 4; Table 2) and also directions
for future research are discussed.
Intracoronary delivery
During routine cardiac catheterization, IC delivery is
performed through the central lumen of an over-wire
balloon catheter that is advanced into the coronary
artery of interest. By using transient balloon inﬂa-
tions, the duration of cell delivery is maximized,
leading to migration of the delivered cells to the
infarct related area. A major advantage of IC delivery
is direct infusion into the target area using infarct
related or a contralateral artery.
Based on animal and patient studies Strauer et al.
looked for a non-surgical method for autologous cell
therapy [7, 49]. In 2002, IC infusion of autologous
BM-MNC appeared to be promising method for cell
delivery in ten patients with acute MI [50]. Since
then, a number of clinical trials have been conducted
[51–60]. These studies showed that IC infusion was a
safe delivery strategy and associated with a modest
increase in myocardial function in patients with
ischemic heart disease. Nevertheless, 5-year follow-
up data of cell therapy demonstrated no signiﬁcant
improvement in left ventricle ejection fraction (EF)
compared to placebo [61, 62]. In 31 clinical studies
performed sofar, 22 used IC infusion as delivery
strategy in approximately 1,200 patients, despite
unresolved issues regarding this transplantation tech-
nique [63].
Important drawbacks of IC delivery are known,
including the impossibility to access to the area of
interest in patients with chronic occlusion. Other
potential disadvantages of IC delivery of cells include
intimal dissection [64, 65], embolization of these
cells from the site of injection to the microvasculature
in the heart leading to micro infarctions [66]o r
abdominal region [6] and in-stent restenosis due to
transient balloon inﬂation [67]. Finally, imprecise
localization and systemic delivery to non-cardiac
tissues are limitations of IC therapy [68]. This can be
explained by inadequate cellular migration into the
myocardium during the ﬁrst transit of coronary
reperfusion causing a considerable loss of cells to
the systemic circulation. A large portion of these cells
are found in non-cardiac tissues, like lungs and liver
[68, 69]. It has been shown that approximately 2% of
the infused non-enriched BM-MNC home to the
target area of cardiac injury in humans [11]. How-
ever, a higher retention (14–39%) in the infarcted
myocardium was observed when using enriched BM-
MNC [11]. This effect may be caused by differences
in injected cell numbers. Notably, most clinical trials
used non-enriched BM-MNC.
Many cell types have been used to treat MI using
IC delivery in the (semi) acute setting. Although
initial results were positive, low delivery efﬁ-
ciency remains an obstacle for clinical application.
Fig. 4 Schematic overview of the different delivery tech-
niques to the injured myocardium. a Intravenous infusion
b Trans-endocardial delivery c Surgical delivery d Intracoro-
nary infusion e Retrograde coronary transvenous injection
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123In general, this technique can not be used in chronic
ischemic heart failure patients with occluded arteries.
In addition, most studies related to IC infusion are
small and lack of long-term follow-up data. In the
future, research should focus on larger, blinded,
randomized trials in MI patients with long-term
follow-up to investigate the immediate and sustained
effect of IC delivery.
Catheterized peripheral vein delivery
Cell delivery can be achieved by direct IV infusion of
cells into a catheterized peripheral vein. Although it
is an easy and safe method for cell delivery [3, 4],
non-cardiac uptake of stem cells after systemic
delivery remains a major obstacle for clinical appli-
cation [27, 69, 70]. Moreover, several studies have
shown that no (0% of injected) cells retained in the
heart (see Table 3). Additionally, the occurrence of
microembolism in non-cardiac organs due to cellular
entrapment of cell types with large diameter (e.g.
skeletal myoblasts or MSC) is an important
drawback.
In our view, this technique is currently obsolete for
clinical cardiac stem cell therapy. In case of future
speciﬁc cardiac targeting of stem cells for optimal
homing and engraftment, this technique can possibly
re-enter the research arena.
Intramyocardial delivery
Nowadays, percutaneous injection of cells for cardiac
repair directly into the injured myocardium is possi-
ble. Two delivery techniques are available for
percutaneous IM injections: trans-endocardial injec-
tion (TE) and retrograde coronary transvenous (RCV)
injection.
Trans-endocardial injection
Five different IM injection catheters are available for
clinical use: Steerjet (MicroHeart) [71], Stiletto
Table 2 Advantages and disadvantages of stem cell delivery methods
Method Advantages Disadvantages
Intracoronary delivery Direct infusion infarct related or contralateral
coronary artery
Well known technique by cardiologists
In-stent restenosis
No access to occluded coronary artery
Embolisation of microvessels, leading to
(micro) infarction
Intima dissection
Vascular access complications
Systemic delivery to non-cardiac tissues
Catheterized peripheral
vein delivery
Non-invasive and easy method
Allows intermittent cell infusion
Microembolism
Low cellular migration and differentiation
Low delivery efﬁciency
Trans-endocardial injection Cell delivery in occluded areas
Implementation of high cell concentration in
the ischemic region
Assess non-viable myocardium before
transplantation
Requires training; lengthen time of procedure
Expensive method
Risk of myocardial perforation
Arrhythmias
Vascular access complications
Retrograde coronary transvenous
injection
Low costs
May enter thinned myocardium due its
co-axial injection technique
May cause irreversible damage to venous wall
Perforation of the vein
Only access to the anterior wall along the vein
Technical difﬁcult procedure
Vascular access complications
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123(Boston Scientiﬁc SciMed, Natick, MA) [10, 72],
Bioheart Myocath (Santa Rosa, CA), the Helix needle
catheter (being developed) (BioCardia, CA) and
Biosense Webster Myostar (Diamond Bar, CA) [5].
All above stated devices are developed for cell and
gene based therapies.
In general, IM injection of cells requires extensive
ﬂuoroscopic guidance to navigate within the ventri-
cle, which is an important drawback for both patient
and operator. To overcome this issue, the Myostar
catheter is incorporated into a three dimensional
electromechanical mapping system (NOGA). The
target area can be determined by identifying viable,
hibernating and infarcted myocardium, without the
need of ﬂuoroscopic guidance. Therapeutic cells can
be injected in the region of interest, that is deﬁned as
a ‘mismatch’ area, i.e. presence of electrical activity
in absence of mechanical movement. The use of the
NOGA system was generally proven to be safe and
feasible in animal studies and clinical trials for
cellular [5, 73] and gene [74, 75] therapy.
Perin et al. evaluated the safety and effect of TE
delivered autologous BM-MNC in patients with
severe heart failure. They observed an improved
regional and global myocardial function compared to
controls, without safety issues [5]. These encouraging
results initiated a number of new trials [76–79].
Other possible advantages of this technique include:
cell delivery in occluded areas and implementation of
high cell concentration in the myocardial region of
interest.Potential drawbacks ofIMdeliveryare therisk
of myocardial perforation due to injection [80]. Fur-
thermore, handling of the NOGA system requires
technical training, is time consuming and expensive
due to the use of a separate mapping and injection
catheter.AnothermajordrawbackofTEinjectionisthat
direct cell injection may alter the gap junction orienta-
tion leading to ventricular arrhythmias [81]. Also, the
ischemic environment and needle puncture may lead to
a release of inﬂammatory stimuli which could be a
trigger for arrhythmias [82]. Cellular retention ranges
from 3 to 54% after TE injection. This wide variety is
due to differences in animal model, TE catheter, cell
type, imaging method and study design (see Table 3).
Over the past years, TE has rapidly evolved from
an experimental technique towards a promising IM
delivery technique. In the coming years research
should focus on determining the most efﬁcient TE
catheter and long-term effects of this strategy.
Retrograde coronary transvenous injection
During a routine transvenous catheterization proce-
dure a roadmap coronary venogram will be per-
formed to gain access to all areas of the heart. Of
note: no left-sided catheterization procedure is nec-
essary for this technique. A composite catheter
(TransAccess, Menlo Park, California) with a nitinol
needle will be inserted into the venous wall under
intravascular ultrasound, followed by microinfusion
of stem cells by an IntraLume (Trans Vascular Inc.)
catheter that will penetrate the myocardium under
ﬂuoroscopic guidance [83]. Thompson et al. [83]
were the ﬁrst to demonstrate the safety and feasibility
of RCV delivery in a non-infarcted swine model. In
addition, retrograde infusion of bone marrow cells
induced angiogenesis and improved cardiac function
in ischemic pigs compared to controls [84]. It was
shown that RCV is a safe and feasible method for
myoblast transplantation in patients 3 months after
MI [85]. The authors also suggested that the RCV
catheter rotates better which may improve target
accuracy compared to TE injection. Furthermore,
RCV is advantageous in cost, time performance
thereby preventing cell loss and may enter thinned
myocardium (\5 mm) due its co-axial injection
technique [83, 84]. However, possible irreversible
damage to the venous wall may occur during the
injection procedure [86] and it is technical difﬁcult to
implement cells in the coronary venous system. With
this technique only access to the anterior wall can be
achieved, and only along the veins anatomy. Incor-
rect position of the needle may cause perforation of
the venous wall leading to a pericardial hemorrhage.
A small number of studies [83–86] have been
conducted, but it is still early to draw a conclusion
regarding the efﬁcacy of RCV.
Other delivery methods
Cell transplantation into the coronary venous system
and the pericardial space has been tested in pre-
clinical models and may have promising clinical
applications in the future. Local intrapericardial
delivery can be achieved by transatrial or subxyphoid
access [87, 88]. Both techniques were well tolerated
without apparent complications. However, to our
knowledge no studies have investigated cell injec-
tions to the injured heart. Moreover, clinical
376 Int J Cardiovasc Imaging (2011) 27:367–383
123experience with this technique is limited. Only one
study has been conducted so far [89].
Coronary sinus venous infusion is performed by
advancing a single or double balloon catheter via the
coronary sinus into the area of interest [31, 90].
Before cell infusion, a detailed anatomical map will
be obtained by a coronary sinus venogram. During
the procedure infusion pressure should be monitored
closely to prevent disruption of the venocappillary
system [91]. Studies have shown that it is feasible to
access most myocardial segments through the cardiac
venous system [92]. Therefore, this technique may be
an alternative for patients with a coronary arterial
occlusion. Compared to IC delivery brief periods of
venous balloon occlusion are unlikely to cause
clinical complaints or myocardial ischemia due to
the existence of venous anastomoses [92]. The
limitations of this approach are similar to RCV
injections.
It was demonstrated that coronary venous infusion
does not produce hemodynamical changes in a
porcine model of myocardial injury. The authors
concluded that this strategy was effective because
autologous unfractioned bone marrow cells were
observed in the myocardium and enhanced angio-
genesis [93]. Later, the same research group con-
ducted a prospective study in 14 patients with chronic
stable angina. Autologous cell infusion was safe and
tolerable. Signiﬁcant improvement in myocardial
perfusion and EF were observed during follow-up.
Coronary angiography showed more collateral ves-
sels in 9/14 patients [94]. However, these results do
not prove efﬁcacy assessed by a randomized trial.
Comparison of delivery techniques
Hou et al. assessed cell distribution of human
mononuclear cells after surgical, IC and coronary
venous delivery in an ischemic swine model. Only
11, 2.6 and 3.2% were retained in the heart after
surgical, IC and venous delivery, respectively [31].
Although surgical delivery appeared to be the most
efﬁcient technique, there was a huge variation in
efﬁciency. The group of Freyman compared allogenic
MSC engraftment after IV, IC and IM (Stiletto)
delivery in a porcine MI model [69]. They found that
IC delivery was associated with signiﬁcant higher
engraftment rates after 14 days compared to IM and
IV. However, decreased coronary bloodﬂow and
greater myocardial injury were observed after IC
delivery. This could be due to high cell numbers
injected. Perin et al. [6] demonstrated that IM
injection (using NOGA technology) of autologous
MSC signiﬁcantly improved left ventricle EF and
reduced myocardial ischemia in a canine model.
Conversely, no change in the IC group was observed.
Another study compared IM and RCV delivery of
microspheres and found no signiﬁcant difference in
myocardial retention between these techniques. The
authors also suggested that IM injection is superior to
RCV in the infarct region, but that RCV is preferred
for treatment of the peri-infarct region were to be
treated based on differences in target areas of the
devices [95]. Recently, it was demonstrated that RCV
injection of BM-MNC is better than IC delivery in
view of cell retention and tissue penetration in an
acute MI model. However, the study is limited by a
very small sample size (n = 2 per group) [96].
In summary, several large animal studies showed
conﬂicting results in the efﬁcacy of different trans-
plantation strategies. Notably, the optimal transplan-
tation technique also depends on type of model (acute
MI vs. chronic heart failure). To provide a deﬁnite
answer to the most optimal delivery strategy, we
believe that a randomized trial in a clinically relevant
animal model (porcine) is necessary, using state-of-
the-art cell tracking techniques, including determina-
tion of biodistribution after the various delivery
strategies.
Conclusion
Cell based cardiac repair showed beneﬁcial effect on
myocardial function in animal experiments. A num-
ber of clinical trials have already been conducted,
although important unresolved issues concerning cell
therapy are present. Interestingly, the most optimal
delivery strategy still needs to be determined. Non-
invasive imaging plays an essential role in determin-
ing biodistribution, survival and functional effects to
the heart, that is of importance for several aspects of
cell therapy (e.g. delivery strategy, cell type). Imag-
ing parameters like contractility, perfusion, and
viability of myocardium do not grant direct visual-
ization of transplanted cells. New advancements in
MRI and nuclear imaging have shown to provide
reliable and highly sensitive visualization of
Int J Cardiovasc Imaging (2011) 27:367–383 377
123transplanted cells, although mainly performed in ani-
malmodels.Theintroductionofmolecularcelltracking
will contribute immensely to future studies of cellular
mechanisms attributable to functional improvement.
Until now, a small number of studies compared
biodistribution between different delivery techniques
in acute MI models. Unfortunately, results are still
inconclusive due to differences in cell type, animal
model, labeling method and delivery techniques.
In view of clinical trials it is important to
determine the most optimal delivery strategy in a
pre-clinical MI model using state-of-the-art cell
tracking for both biodistribution and long-term sur-
vival. Adequate cell tracking is essential to guide
molecular approaches to enhance homing, engraft-
ment and survival of transplanted stem cells. There-
fore, additional and more focused pre-clinical studies
are mandatory before designing new clinical trials.
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